Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. With the acquisition of Finetech Medical Limited and Bioinduction Ltd in 2023, we are continuing to be the only UK based company in the field of designing and manufacturing long-term implantables.
We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation.
Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.
Company Details
- Employees
- 45
- Founded
- -
- Address
- 242 Acklam Road, London,england W10 5yg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.amber-tx.com
- HQ
- London, England
Amber Therapeutics Questions
Amber Therapeutics's website is http://www.amber-tx.com
Amber Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/amber-therapeutics
Amber Therapeutics has
45 employees.
View email and phone details for 45
employees at Amber Therapeutics.
Amber Therapeutics's industry is
Biotechnology Research
Amber Therapeutics's top competitors are
Caldera,
Dispatch,
Chamber,
Cellclar Cic,
Cartwheel,
Syvento Biotech,
Smarterdx,
Pogo,
Eyebio,
Ensocell.
Amber Therapeutics's categories are Biotechnology Research
Amber Therapeutics's founding year is 2021
